GlassScriptPhysician profile
Donald Charles Vile
NPI 1366862484
$887.82
in general payments reported to CMS, 2019-2025
17 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2021: $32.58 · 2022: $101 · 2023: $166 · 2024: $204 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531 · Education: $11.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.30 |
| Education | $11.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $296.21 | 2023-2025 | |
| Seagen INC. | $126.04 | 2019-2023 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $111.49 | 2019 | |
| Celgene Corporation | $70.44 | 2022-2023 | Reblozyl, Pomalyst |
| Pfizer INC. | $57.26 | 2024-2025 | |
| Tactile Systems Technology INC | $56.17 | 2022 | |
| Puma Biotechnology, INC. | $40.29 | 2021-2022 | |
| Janssen Biotech, INC. | $32.71 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Beone Medicines USA, INC. | $27.19 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $22.34 | 2025 | Datroway |
| Abbvie INC. | $19.54 | 2023 | Venclexta |
| Amgen INC. | $16.22 | 2023 | Lumakras |
| Gilead Sciences, INC. | $11.92 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Vile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.